scholarly journals Treatment with Sunitinib for Patients with Progressive Metastatic Pheochromocytomas and Sympathetic Paragangliomas

2012 ◽  
Vol 97 (11) ◽  
pp. 4040-4050 ◽  
Author(s):  
Montserrat Ayala-Ramirez ◽  
Cecile N. Chougnet ◽  
Mouhammed Amir Habra ◽  
J. Lynn Palmer ◽  
Sophie Leboulleux ◽  
...  
Keyword(s):  
Clinical Benefit ◽  
Fdg Pet ◽  
Progression Free Survival ◽  
Cancer Center ◽  
Free Survival ◽  
Recist 1.1 ◽  
Dismal Prognosis ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Context: Patients with progressive metastatic pheochromocytomas (PHEOs) or sympathetic paragangliomas (SPGLs) face a dismal prognosis. Current systemic therapies are limited. Objectives: The primary end point was progression-free survival determined by RECIST 1.1 criteria or positron emission tomography with [18F]fluorodeoxyglucose/computed tomography ([18F]FDG-PET/CT), in the absence of measurable soft tissue targets. Secondary endpoints were tumor response according to RECIST criteria version 1.1 or FDG uptake, blood pressure control, and safety. Design: We conducted a retrospective review of medical records of patients with metastatic PHEO/SPGL treated with sunitinib from December 2007 through December 2011. An intention-to-treat analysis was performed. Patients and Setting: Seventeen patients with progressive metastatic PHEO/SPGLs treated at the Institut Gustave-Roussy and MD Anderson Cancer Center. Interventions: Patients treated with sunitinib. Results: According to RECIST 1.1, eight patients experienced clinical benefit; three experienced partial response, and five had stable disease, including four with predominant skeletal metastases that showed a 30% or greater reduction in glucose uptake on [18F]FDG-PET/CT. Of 14 patients who had hypertension, six became normotensive and two discontinued antihypertensives. One patient treated with sunitinib and rapamycin experienced a durable benefit beyond 36 months. The median overall survival from the time sunitinib was initiated was 26.7 months with a progression-free survival of 4.1 months (95% confidence interval = 1.4–11.0). Most patients who experienced a clinical benefit were carriers of SDHB mutations. Conclusion: Sunitinib is associated with tumor size reduction, decreased [18F]FDG-PET/CT uptake, disease stabilization, and hypertension improvement in some patients with progressive metastatic PHEO/PGL. Prospective multi-institutional clinical trials are needed to determine the true benefits of sunitinib.

scholarly journals Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Lymphoblastic Lymphoma is an Independent Prognostic Factor with an Impact on Progression-Free Survival but not Overall Survival

2021 ◽  
Vol 20 ◽  
pp. 153303382110564
Author(s):  
Na Dai ◽  
Hang Liu ◽  
Shengming Deng ◽  
Shibiao Sang ◽  
Yiwei Wu
Keyword(s):  
Prognostic Factor ◽  
Fdg Pet ◽  
Progression Free Survival ◽  
Lymphoblastic Lymphoma ◽  
Emission Tomography ◽  
Free Survival ◽  
Positron Emission ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Purpose: In the present study, we mainly aimed to evaluate the prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose ([18F]F-FDG) positron emission tomography (PET)/computed tomography (CT) after allogeneic stem cell transplantation (allo-SCT) in lymphoblastic lymphoma (LBL) patients using Deauville Scores (DS). Materials and Methods: A total of 63 LBL patients who benefited from 18F-FDG PET-CT after allo-SCT in our institution between April 2010 and August 2020 were enrolled in this retrospective study. These above-mentioned patients were divided into two groups based on the Deauville criteria. Diagnostic efficiency of 18F-FDG PET/CT and integrated CT in detecting lymphoma were calculated. Consistencies were evaluated by comparing 18F-FDG PET/CT and integrated CT results through kappa coefficient. Kaplan-Meier method was used in survival analysis, and the log-rank method was adopted in comparisons. Prognostic factor analysis was performed by the Cox regression model. Results: The sensitivity, specificity, positive predictive value, negative predictive value, accuracy of post-SCT 18F-FDG PET-CT were 100%(12/12), 92.2%(47/51), 75.0%(12/16), 100%(47/47) and 93.7%(59/63). The consistency of 18F-FDG PET-CT and integrated CT was moderate(Kappa = .702，P < .001). Positive post-SCT 18F-FDG PET-CT was associated with lower progression-free survival (PFS) but not overall survival (OS) (p = .000 and p = .056, respectively). The 3-year PFS of the PET-positive group and PET-negative group was 18.8% and 70.2%, respectively. Multivariate analysis showed that post-SCT PET-CT findings was an independent prognostic factor for PFS (p = .000; HR, 3.957; 95%CI, 1.839-8.514). Other factors independently affecting PFS were sex (p = .018; HR, 2.588; 95% CI, 1.181 − 5.670) and lactate dehydrogenase (LDH) (p = .005; HR, 3.246; 95% CI, 1.419 − 7.426). However, none of the above-mentioned factors were associated with OS. Conclusions: Collectively, we found that 18F-FDG PET-CT after allo-SCT was a strong indicator for PFS, but not OS, which might provide important evidence for the selection of subsequent treatment regimen for LBL patients. Trial registration number: ChiCTR2100046709.

scholarly journals [18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis

2017 ◽  
Vol 18 (1) ◽  
Author(s):  
Aurélien Justet ◽  
Astrid Laurent-Bellue ◽  
Gabriel Thabut ◽  
Arnaud Dieudonné ◽  
Marie-Pierre Debray ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Fdg Pet ◽  
Progression Free Survival ◽  
Free Survival ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Diagnostic and prognostic value of 99mTc-Tektrotyd scintigraphy and 18F-FDG PET/CT in a single-center cohort of neuroendocrine tumors

2021 ◽  
Author(s):  
Jelena Saponjski ◽  
Djuro Macut ◽  
Nebojša Petrovic ◽  
Sanja Ognjanovic ◽  
Bojana Popovic ◽  
...  
Keyword(s):  
False Positive ◽  
Fdg Pet ◽  
False Negative ◽  
Progression Free Survival ◽  
True Positive ◽  
True Negative ◽  
Free Survival ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

IntroductionThe aim was to assess the diagnostic value of 99mTc-Tektrotyd scintigraphy (TCT) and positron emission tomography/computed tomography using F-18 fluorodeoxyglucose (18F-FDG PET/CT) in the detection and follow-up of neuroendocrine tumors (NETs), and their predictive value for disease progression.Material and methodsIn this retrospective cohort, TCT and 18F-FDG PET/CT were performed in 90 patients (37 men, 53 women, mean age 52.7 ±15.1), with NET. Correlation of Ki67 and tumor grade versus Krenning score and SUVmax was assessed, Kaplan-Meier analysis was used for progression-free survival (PFS), and Cox regression analysis was performed to identify the association between progression-related factors and PFS.ResultsOut of 90, true positive TCT was detected in 56 (62.2%) patients, true negative in 19 (21.1%), false positive in 4 (4.4%), false negative in 11 (12.2%), while 18F-FDG PET/CT was true positive in 69 (76.7%) patients, true negative in 10 (11.1%), false positive in 5 (5.5%), false negative in 6 (6.7%). Mean 18F-FDG PET/CT SUVmax was 6.8 ±6.2. Diagnostic sensitivity of TCT was 83.6%, specificity 82.6%, accuracy 83.3% vs. 18F-FDG PET/CT sensitivity was 92.0%, specificity 66.7%, accuracy 87.8%. A significant correlation between Ki67 and SUVmax was found in positive 18F-FDG PET/CT findings, unlike the correlation between Ki67 and Krenning score. Median PFS was 25 months (95% CI: 18.2–31.8), in 18F-FDG PET/CT positive patients 23 months (95% CI: 16.3–29.7) and 18F-FDG PET/CT negative 26 months (p = 0.279). Progression-free survival predictors were SUVmax and Krenning score.ConclusionsIn our study, TCT and 18F-FDG PET/CT have high diagnostic accuracy in detection of NET. Higher Krenning score on TCT and SUVmax in positive 18F-FDG PET/CT findings are predictors of disease progression. 99mTc-Tektrotyd scintigraphy and 18F-FDG PET/CT can be useful complementary tools in management of patients with NETs and in predicting patients’ outcome.

Vai trò của chẩn đoán hình ảnh thông thường và 18F-FDG PET/CT trong đánh giá đáp ứng điều trị ung thư

2021 ◽  
Vol 16 (DB4) ◽  
Author(s):  
Lê Ngọc Hà ◽  
Mai Hồng Sơn
Keyword(s):  
Fdg Pet ◽  
Recist 1.1 ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Mục tiêu của bài viết này là nêu lên các ứng dụng thực hành và những hạn chế của việc đánh giá đáp ứng điều trị của các ung thư dạng đặc dựa trên các tiêu chuẩn chẩn đoán hình ảnh. Hiện nay, có rất nhiều tiêu chuẩn đánh giá bao gồm tiêu chuẩn của Tổ chức Y tế Thế giới (WHO), tiêu chuẩn đánh giá đáp ứng của u dạng đặc (RECIST; RECIST 1.1). Gần đây đánh giá định tính và định lượng dựa vào chuyển hóa FDG trong ung thư sử dụng PET/CT toàn thân, trở nên một phương pháp quan trọng để đánh giá đáp ứng điều trị ung thư dạng đặc (tiêu chuẩn PERCIST phiên bản 1.0). Phương pháp đánh giá dựa vào hình ảnh giải phẫu của WHO, RECIST, RECIST 1.1 được sử dụng rộng rãi những vẫn còn nhiều hạn chế trong đánh giá đáp ứng với điều trị. Tiêu chuẩn RECIST cho thấy sự tiến triển của khối u chậm hơn so với tiêu chuẩn của WHO. RECIST 1.1 có giá trị cao hơn tiêu chuẩn RECIST trong đánh giá đáp ứng điều trị với tổn thương hạch. 18F-FDG PET/CT cho phép đánh giá định tính và định lượng chuyển hóa ở khối u dựa vào chuyển hoá như chỉ số SUV.

scholarly journals Positron Emission Tomography for the Response Evaluation following Treatment with Chemotherapy in Patients Affected by Colorectal Liver Metastases: A Selected Review

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Alberto Zaniboni ◽  
Giordano Savelli ◽  
Claudio Pizzocaro ◽  
Pietro Basile ◽  
Valentina Massetti
Keyword(s):  
Liver Metastases ◽  
Fdg Pet ◽  
Therapy Response ◽  
Progression Free Survival ◽  
Free Survival ◽  
Positron Emission ◽  
Response To Chemotherapy ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Ct And Mri

The aim of the present paper is to review the scientific literature concerning the usefulness of18F-FDG PET/CT in the evaluation of response to chemotherapy in patients affected by liver metastases from colorectal cancer.Material and Methods. Studies were identified by searching PubMed electronic databases. Both prospective and retrospective studies were included. Information regarding the figure of merit of PET for the evaluation of therapy response was extracted and analyzed.Results. Existing data suggests that18F-FDG PET/CT may have an outstanding role in evaluating the response. The sensitivity of PET in detecting therapy response seems to be greater than conventional imaging (CT and MRI). PET/CT response is strictly related to better overall survival and progression-free survival.Conclusions. PET/CT is more than a promising technique to assess the response to chemotherapy in colorectal and liver metastases. However, to be fully validated, this examination needs further studies by recruiting more patients.

FDG-PET/CT is Predictive of Progression-free Survival in Anal Cancer

2009 ◽  
Vol 75 (3) ◽  
pp. S258-S259
Author(s):  
W.W. Lien ◽  
A.R. Rao ◽  
J.S. Kaptein ◽  
M.A. Tome
Keyword(s):  
Anal Cancer ◽  
Fdg Pet ◽  
Progression Free Survival ◽  
Free Survival ◽  
Pet Ct ◽  
Fdg Pet Ct
Sign in / Sign up

Export Citation Format

Share Document